Oaklawn Park ejects trainer Ingrid Mason after syringe possession reported

Oaklawn Park has excluded trainer Ingrid Mason from its grounds after investigators reported finding needles, syringes and an injectable product called Movex in her barn area, a move that raises fresh questions about medication controls and oversight at race meets. The Association of Racing Commissions International posted that Mason was “ejected by Oaklawn Park Security on February 5, 2026,” and that the Oaklawn Park Board of Stewards excluded her “until such time that Oaklawn management approves her re-admittance to Oaklawn Park's property.” The ARCI notice also states Ms. Mason “agreed to waive her right to a Stewards hearing in this matter.”

Mason has acknowledged the encounter with investigators. She told the Paulick Report that investigators “caught her with needles, syringes, and an injectable product called 'Movex.'” Mason is quoted as saying, “It was my fault,” and “I don't know why I took a chance with something like that.” Paulick and other industry outlets identified Movex as a chondroitin 4 sulfate injectable product; the ARCI posting itself set the official exclusion but did not specify a time period for the ban.

The action against Mason comes in the context of heightened enforcement by the Horseracing Integrity and Welfare Unit, the enforcement arm of the Horseracing Integrity and Safety Authority. That unit and Oaklawn security have been active at recent compliance inspections. Reporting tied to a separate Jan. 29 inspection found two hypodermic syringes in the lower console of a truck belonging to exercise rider and trainer Eusebio Juarez-Rufino. Those syringes measured 35 ml and 12 ml, contained a clear liquid that tested positive for diisopropylamine, and prompted a two-year suspension and $18,000 in fines that were later stayed by a judge while legal challenges proceeded.

Industry reporting has not been entirely consistent. Some outlets, citing Paulick, ran headlines saying Mason “has been banned from Oaklawn Park for five years.” The ARCI posting, however, does not state a five-year term; it frames the exclusion as effective until Oaklawn management approves re-admittance and notes Mason waived a stewards hearing. That discrepancy underscores an immediate reporting gap owners, trainers and bettors will want clarified by Oaklawn and regulators.

Beyond the immediate personnel fallout, the episode has business and cultural implications for racing. Enforcement actions that involve injectable products and syringes test trust in medication governance at tracks and can influence owner decisions about where to stable horses, impact trainer reputations, and shift wagering sentiment. For smaller trainers and exercise riders such as Eusebio Juarez-Rufino, the specter of laboratory-confirmed substances like diisopropylamine - described in industry reporting as a vasodilator banned under HIWU rules - signals higher legal and financial stakes for handling medications and equipment.

For fans and participants, the next steps matter: Oaklawn management and the stewards must clarify the exact terms of Mason’s exclusion, whether Movex or any seized items were lab-tested, and whether formal HIWU charges will follow. The outcomes will shape enforcement precedent at Oaklawn and beyond, influence relationships between trainers and regulatory authorities, and either restore confidence in medication control or deepen concerns about consistency and transparency in enforcement.